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RCAN1, also known as DSCR1, is an endogenous regulator of calcineurin, a serine/threonine protein phosphatase that plays a 
critical role in many physiological processes. In this report, we demonstrate that p38 MAP kinase can phosphorylate RCAN1 
at multiple sites in vitro and show that phospho-RCAN1 is a good protein substrate for calcineurin. In addition, we found that 
unphosphorylated RCAN1 noncompetitively inhibits calcineurin protein phosphatase activity and that the phosphorylation of 
RCAN1 by p38 MAP kinase decreases the binding affinity of RCAN1 for calcineurin. These findings reveal the molecular 
mechanism by which p38 MAP kinase regulates the function of RCAN1/calcineurin through phosphorylation. 
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Calcineurin (CN) is a Ca2+/calmodulin-dependent serine/ 
threonine protein phosphatase with roles in myriad physio-
logical functions [13], including T cell activation [4], 
apoptosis [5], skeletal myocyte differentiation [6], neuronal 
synaptic plasticity [7], memory formation [8], and cardiac 
health [9]. The most thoroughly characterized calcineurin 
substrates are the nuclear factor of activated T cells (NFAT) 
family transcription factors. Two distinct calcineurin dock-
ing motifs from NFAT, the PxIxIT and LxVP binding mo-
tifs, have been identified [1013]. The PxIxIT motif is pro-
posed to be the main calcineurin binding site, and it is pre-
sent in many other calcineurin substrates and regulatory 
proteins. NFAT transcription factors are expressed in most 
immune cell types and play a central role in the regulation 
of cytokine gene expression. The localization of NFAT is 
regulated by its phosphorylation status. Calcineurin depho- 
sphorylates multiple residues within the regulatory domain 
of NFAT, leading to its nuclear translocation and the activa-
tion of target genes including PTGS2 (COX-2) and TNF- 
(TNFA) [11,14].  
The regulation of calcineurin phosphatase activity by 
cellular inhibitors may have potential as novel modulators 
for the treatment of calcineurin-related diseases. Several 
endogenous proteins can inhibit the catalytic activity of cal-
cineurin. Modulatory calcineurin interacting proteins (also 
called RCAN proteins) are unique among these proteins in 
terms of their expression pattern, and they function in a 
negative feedback loop to regulate calcineurin activity. The 
RCAN proteins comprise a family of endogenous calcineu-
rin regulators that are conserved from yeast to humans and 
are essential for normal calcineurin signaling. Previous 
studies have shown that RCAN1 phosphorylation alters its 
effect on calcineurin. Human RCAN1 is encoded within the 
Down syndrome critical region on chromosome 21. It is 
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abundantly expressed in the heart, brain, and muscles, and it 
is overexpressed in the brains of individuals with Down 
syndrome and Alzheimer’s disease [15,16]. Recently, 
RCAN1 has been highlighted because of its possible func-
tional link with vertebrate embryonic development and tu-
mor progression [1719].  
In the present study, we demonstrate for the first time 
that p38 MAP kinase directly phosphorylates RCAN1 at 
five sites (S93, S108, S112, T124 and T153) in vitro. We 
conducted kinetic studies on the phospho-RCAN1 protein 
and demonstrated that it is a good substrate for calcineurin. 
We further show that the phosphorylation of RCAN1 by 
p38 MAP kinase decreases its binding affinity for cal-
cineurin, suggesting that phosphorylation may relieve the 
inhibition of calcineurin signaling by RCAN1.  
1  Materials and methods 
1.1  Materials 
Tris, bacterial purine nucleotide phosphorylase, the materi-
als used to generate the purine nucleotide phosphorylase 
substrate 7-methyl-6-thioguanosine (MESG), CaCl2, and 
MnCl2 were purchased from Sigma (St. Louis, MO). 3-(N- 
morpholino) propanesulfonic acid (MOPS), bovine serum 
albumin (BSA), dithiothreitol (DTT), and NaCl were ob-
tained from Amresco (Solon, OH). MESG was synthesized 
as described previously [20]. 
1.2  Plasmid construction and the expression and puri-
fication of mouse calcineurin α, RCAN1, p38α MAP ki-
nase, calmodulin (CaM) and p-inhibitor-1 
Mouse CNAα and CNB1 were cloned into pET-21b vectors 
(Novagen) with a C-terminal His6-tag and a chloromyce-
tin-resistant pACYCDuet vector, respectively. The two 
plasmids encoding CNAα and CNB1 were co-transformed 
into BL21 (DE3) competent cells to express a mouse CNα 
heterodimer (mCNα). cDNA encoding mouse RCAN1 was 
kindly provided by Dr. Beverly Rothermel (University of 
Texas, Southwestern Medical Center, Dallas, TX, USA), 
and cloned into a pGEX6P1 expression vector with a 
C-terminal His6-tag. RCAN1 mutants were constructed us-
ing QuikChange site-directed mutagenesis with the 
pGEX6P1-RCAN1 plasmid as a template. Mouse CaM was 
cloned into a modified pGEX4T-2 vector containing an 
N-terminal GST-tag and a PreScission protease cleavage 
site. The expression and purification of bisphosphorylated 
p38α MAP kinase were described previously [21]. Phos-
phorylated inhibitor-1 was obtained by co-expressing His6- 
tagged human inhibitor-1 (1-171) plasmid with non-tagged 
mouse PKAc. Each protein was expressed at 25C and  
initially purified by Ni-NTA (Qiagen) or glutathione-     
Sepharose (GE Healthcare) affinity columns, followed by 
anion exchange and gel filtration chromatography (Source- 
15Q and Superdex-200, GE Healthcare). The affinity tag 
was proteolytically removed from the fusion proteins as 
indicated. Protein stocks for kinetic analysis were supple-
mented with glycerol at a final concentration of 20% (v/v). 
Protein concentrations were determined based on the theo-
retical molar extinction coefficients at 280 nm. 
1.3  In vitro phosphorylation of wildtype (WT) and 
mutant RCAN1 
The C-terminally His6-tagged WT or mutant RCAN1 (40 
µmol L1 each) were phosphorylated in a kinase buffer (50 
mmol L1 MOPS, pH 7.4, 100 mmol L1 NaCl, 0.1 mmol L1 
EDTA, 10 mmol L1 MgCl2, and 1 mmol L1 ATP) with 2 
µmol L1 p38α MAP kinase at 25°C for 30 min. The reac-
tion was terminated at 2, 5, 10 or 30 min. The proteins were 
resolved by SDS-PAGE, and protein phosphorylation was 
indicated by a band shift.  
Recombinant GST-RCAN1 proteins were purified with 
glutathione-Sepharose beads according to the manufactur-
er’s instructions (Amersham Biosciences). The GST-tagged 
RCAN1 was phosphorylated by p38α MAP kinase at 25°C 
for 120 min, and the system was replenished with 1 mmol L1 
ATP every 30 min. Then, the proteins were loaded onto 
glutathione-Sepharose beads and washed three times with 
buffer (50 mmol L1 Tris pH 8.0 and 150 mmol L1 NaCl). 
The GST tags were digested with PreScission protease 
overnight at 4°C. Gel filtration chromatography (Super-
dex-200, GE Healthcare) was performed to further purify 
the phosphorylated RCAN1. 
1.4  In-gel digestion for mass spectrometry 
To identify phosphorylation sites on p-RCAN1 WT and 
S108A/S112A, samples were separated by SDS-PAGE. The 
gel bands corresponding to the targeted proteins were ex-
cised from the gel, reduced with 25 mmol L1 DTT and al-
kylated with 55 mmol L1 iodoacetamide. Then, in-gel di-
gestion was performed with sequencing grade modified 
trypsin (Promega, Fitchburg, WI) in 50 mmol L1 ammo-
nium bicarbonate at 37C overnight. The peptides were ex-
tracted twice with 1% trifluoroacetic acid in 50% acetoni-
trile aqueous solution for 30 min. The extraction mixtures 
were then concentrated by SpeedVac. 
1.5  Liquid chromatography-mass spectrometry (LC-MS)/ 
MS analysis 
For LC-MS/MS analysis, the digestion product was sepa-
rated by a 65 min gradient elution at a flow rate of 0.250 µL 
min1 with the EASY-nLCII™ integrated nano-HPLC sys-
tem (Proxeon, Denmark), which has a direct interface with 
the Thermo LTQ-Orbitrap mass spectrometer. The analyti-
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cal column was a homemade fused silica capillary column 
(75 µm ID, 150 mm length; Upchurch, Oak Harbor, WA) 
packed with C-18 resin (300 Å, 5 µm, Varian, Lexington, 
MA). Mobile phase A consisted of 0.1% formic acid, and 
mobile phase B consisted of 100% acetonitrile and 0.1% 
formic acid. The LTQ-Orbitrap mass spectrometer was op-
erated in data-dependent acquisition mode using the Xcali-
bur 2.0.7 software. A single full-scan mass spectrum was 
conducted in the Orbitrap (400–1800 m/z, 30000 resolution), 
followed by 20 data-dependent MS/MS scans in the ion trap 
at 35% normalized collision energy (CID) or 3 MS/MS 
scans in the quadrupole collision cell with higher energy 
collision dissociation (HCD). MS/MS spectra from each 
LC-MS/MS run were searched against the selected database 
using an in-house Mascot or Proteome Discovery search 
algorithm.  
1.6  Calcineurin phosphatase assay 
All experiments were performed at 25°C in 1.8 mL reaction 
mixtures, and the time courses of absorbance changes were 
recorded using a Lambda 14 Perkin-Elmer spectrophotom-
eter equipped with a magnetic stirrer in the cuvette holder. 
Initial rates were determined from the linear slope of the 
progress curves obtained, and the experimental data were 
analyzed using a nonlinear regression analysis program.  
Phosphatase activity against p-RCAN1 and p-inhibitor-1 
was detected by a continuous spectrophotometric assay. In 
this coupled system [22], the phosphate was transferred 
from p-RCAN1 or p-inhibitor-1 to 7-methyl-6-thioguano- 
sine (MESG) by purine nucleoside phosphorylase. The re-
action mixture contained 50 mmol L1 MOPS pH 7.0, 100 
mmol L1 NaCl, 0.1 mmol L1 EDTA, 50 μmol L1 MESG, 
0.1 mg mL1 purine nucleoside phosphorylase, 1 mmol L1 
CaCl2, 2 mmol L
1 MnCl2, 0.5 mg mL1 BSA, 1 mmol L1 
DTT, and a range of concentrations of phospho-protein sub-
strates, 10 μmol L1 of CaM was added to the p-RCAN1 
assay and 1 μmol L1 CaM was added to the p-inhibitor-1 
assay. Dephosphorylation was detected by monitoring   
the absorbance change at 360 nm caused by the conversion 
of MESG to 7-methyl-6-thioguanine in the presence of   
inorganic phosphate. The quantitation of the phosphate  
release in the dephosphorylation reaction was thus deter-
mined using the extinction coefficient of 11200 M1 cm1  
at 360 nm [23].  
2  Results 
2.1  RCAN1 noncompetitively inhibits calcineurin 
phosphatase activity 
RCANs represent a new class of endogenous calcineurin 
inhibitors [24,25]. RCAN1 may competitively inhibit the 
calcineurin-NFAT pathway in vivo because RCAN1 and 
NFATs share an SP repeat motif and a PxIxIT motif. Re-
cently, Chan et al. [26] demonstrated an inhibitory effect of 
human RCAN1 on calcineurin that competitively inhibited 
calcineurin activity against para-Nitrophenylphosphate 
(pNPP) substrate, a chromogenic compound. pNPP is a 
small-molecule substrate, and interference with this sub-
strate strongly suggests a direct interaction between RCAN1 
and the enzyme active site. To further examine whether the 
competitive inhibition is unique to small molecule aryl 
phosphates, we used a protein substrate, phospho-inhibitor- 
1, to evaluate the inhibitory properties of RCAN1 against 
calcineurin. Protein phosphatase inhibitor-1 is a prototypical 
mediator of cross talk between protein kinases and protein 
phosphatases. The activation of cAMP-dependent protein 
kinase results in the phosphorylation of inhibitor-1 at 
Thr-35, converting it to a protein substrate for calcineurin. 
For inhibition studies, the phospho-inhibitor-1 concentration 
was constant at 3.3 mol L1, and the RCAN1 concentration 
was varied. The dephosphorylation of phospho-inhibitor-1 
was measured using a continuous inorganic phosphate assay 
in which the Pi produced by calcineurin is captured by pu-
rine ribonucleoside phosphorylase in the presence of a pu-
rine ribonucleoside substrate [22]. Figure 1 shows the ef-
fects of RCAN1 on the dephosphorylation of inhibitor-1 by 
calcineurin. A dose-response curve based on increasing 
concentrations of RCAN1 demonstrated that RCAN1 inhib-
ited calcineurin activity (inset of Figure 1). However, the 
enzymatic activity decreased with an increase in the con-
centration of RCAN1 and approached a non-zero constant, 
indicating that binding of RCAN1 only partially inhibited 
calcineurin phosphatase activity against phospho-inhibitor-1. 
The apparent dissociation constant, Ki, for the calcineurin 
inhibition reaction was (0.420.01) mol L1. 
 
 
Figure 1  RCAN1 inhibits p-inhibitor-1 dephosphorylation by calcineurin 
in vitro. The figure shows the time courses of p-inhibitor-1 dephosphoryla-
tion by calcineurin with 0 (curve 1), 2 (curve 2) or 8 μmol L1 (curve 3) 
RCAN1 and 3.3 μmol L1 p-inhibitor-1. The calcineurin concentration used 
for the p-inhibitor-1 assay was 0.192 μmol L1. The inset shows the de-
pendence of the inhibition of calcineurin-catalyzed p-inhibitor-1  
dephosphorylation on the concentration of RCAN1. 
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2.2  RCAN1 is phosphorylated by p38α MAP kinase at 
multiple residues 
A previous study identified two S residues in human 
RCAN1, S108 and S112, as substrates of glycogen synthase 
kinase 3β (GSK-3β) and ERK2 MAP kinase, respectively 
[27]. These residues lie within the highly conserved 
FLISPPxSPP signature motif of the RCAN family. To in-
vestigate whether p38 MAP kinase could also phosphory-
late RCAN1, in vitro kinase reactions were performed with 
either WT or mutant (S108A, S112A or S108A/S112A) 
recombinant RCAN1 proteins and recombinant activated 
p38 MAP kinase in a kinase assay buffer containing ATP 
and Mg2+, and the electrophoretic mobility of RCAN1 was 
determined by SDS-PAGE (Figure 2). At the appropriate 
time points, aliquots of the reaction mixture were with-
drawn, and the reaction was terminated with an equal vol-
ume of 2× Laemmli SDS sample buffer, followed by sepa-
ration on a 15% SDS-PAGE gel. As shown in Figure 2B, 
RCAN1 exhibited a time-dependent change in phosphoryla-
tion, as indicated by the electrophoretic mobility shift. The 
p38 MAP kinase-catalyzed phosphorylation was nearly 
100% complete at 30 min, and the fully phosphorylated 
RCAN1 protein ran as a single band on a 15% SDS-PAGE 
gel.  
To identify specific RCAN1 residues that were phos-
phorylated by p38α MAP kinase, we purified the p38α 
MAP kinase-phosphorylated RCAN1 WT and RCAN1 
S108A/S112A proteins and performed electrospray mass 
spectrometry. As shown in Figure 3 and Figure 4, elec-
trospray spectrometry of a tryptic digestion of phospho- 
RCAN1 revealed five phosphorylation sites in WT RCAN1 
(S93, S108, S112, T124 and T153) (Figure 3) and three 
sites in RCAN1 S108A/S112A (S93, T124 and T153) (Fig-
ure 4).  
2.3  p38α MAP kinase-phosphorylated RCAN1 is a 
good substrate for calcineurin 
We next determined whether p38α MAP kinase-phosphor- 
ylated RCAN1 could serve as a calcineurin substrate using a 
continuous spectrophotometric assay. In this method, the 
phosphorylation level of RCAN1 was measured by the 
amount of inorganic phosphate released from RCAN1 after 
treatment with calcineurin. The inorganic phosphate pro-
duced was monitored continuously by a coupled enzyme 
assay using purine nucleoside phosphorylase and its chro-
mophoric substrate, MESG, and quantitated using the ex-
tinction coefficient of 11200 M1 cm1 at 360 nm. Figure 5A 
shows time courses for the dephosphorylation of phos-
pho-RCAN1 by calcineurin. The data in this figure show 
that the calcineurin-catalyzed reaction was nearly 100% 
complete in 15 min. When all of the substrate had been 
converted to product, the phosphorylation stoichiometry of 
RCAN1 was determined to be close to 5 mol phosphate/mol 
RCAN1. As expected, only 3 equivalents of inorganic 
phosphate were released upon treatment of the S108A/ 
S112A mutant with calcineurin. These results further sup-
port our conclusion that p38α MAP kinase can phosphory-
late RCAN1 at multiple residues in vitro. 
To further characterize the biochemical properties of 
phospho-RCAN1, we measured the kinetic parameters of 
the calcineurin-catalyzed reaction using phosphorylated 
RCAN1 and the S108A/S112A mutant as substrates. All 
steady-state kinetic studies were performed at pH 7.0 and 
25°C. The initial rates of the dephosphorylation reaction 
were determined from the slopes of the initial linear portion 
of the progress curves. Figure 5B shows the initial rates of 
the calcineurin-catalyzed reaction at different RCAN1 con-
centrations. Because the concentrations of RCAN1 and cal-
cineurin were comparable in the reaction, the assumption 
that the free substrate concentration was equal to the total 
substrate concentration could not be made. Thus, the kinetic 
data were analyzed using the general initial velocity equa-
tion, taking substrate depletion into account.  
 
 
Figure 2  Phosphorylation of RCAN1 by p38α MAP kinase. A, Phos-
phorylation sites for MAPK and GSK-3β are present in the SP repeat of 
RCAN1. The serine phosphorylated by MAPK is shown in green, while the 
GSK-3β phosphorylation site is shown in cyan. The LxVP docking site, SP 
motif and PxIxIT docking sites are shown in purple, blue and red, respec-
tively. B, Time courses of RCAN1 WT and mutant phosphorylation by 
p38α MAP kinase. RCAN1 was phosphorylated in an in vitro phosphoryla-
tion system (see “Materials and methods”) containing 40 μmol L1 RCAN1 
and 2 μmol L1 p38α MAP kinase. 
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Figure 3  Identification of p38α MAP kinase phosphorylation sites of RCAN1 by mass spectrometry. A, The MS/MS spectrum of a triply charged ion at 
m/z 796.39 for MH3
3+ corresponding to the mass of the mono-phosphorylated peptide LYFAQTLHIGSSHLAPPNPDK. A loss of 98 Da (H3PO4) was ob-
served for the precursor ion under the higher energy collision dissociation (HCD). The labeled peaks correspond to the masses of the y and b ions of the 
modified peptides. The y10 ion was observed to have high intensity compared to the phosphorylated y10 ion, as shown in the inserted figure, suggesting that 
Ser-11 is the major phosphorylated residue. B, The MS/MS spectrum of a triply charged ion at m/z 595.61 for MH3
3+ corresponding to the mass of the 
di-phosphorylated peptide QFLISPPASPPVGWK. The labeled peaks correspond to the masses of the b and y ions of the di-phosphorylated peptide, indicat-
ing that both Ser residues are phosphorylated. C, The MS/MS spectrum of a triply charged ion at m/z 739.36 for MH3
3+ corresponding to the mass of the 
mono-phosphorylated peptide qVEDATPVINYDLLYAISK (in which the first residue Gln is a pyroglutamine). The labeled peaks correspond to the masses 
of the b and y ions of the mono-phosphorylated peptide, indicating that phosphorylation is on the Thr-6 residue. D, The MS/MS spectrum of a triply charged 
ion at m/z 1328.55 for MH3
3+, corresponding to the mass of a mono-phosphorylated peptide YELHAATDPTPSVVVHVCESDQENEE- EEEEMER in which 
the Cys was carbamidomethylated and the Met was oxidized. The loss of 98 Da (H3PO4) was observed for precursor ions under CID. The labeled peaks  
correspond to the masses of the b and y ions of the mono-phosphorylated peptide, indicating that phosphorylation is on the Thr-10 residue. 
 cat 20 0 0 m 0 0 m 0 0[ ] [ ] [ ] [ ] 4[ ] [ ] .2kv S E K E S K E S            
(1)                             
Direct curve fitting of the data to eq. (1) yielded the kcat and 
Km values for the dephosphorylation of RCAN1 and the 
S108A/S112A mutant by calcineurin (Table 1). The Km 
values are approximately 7-fold greater than the inhibition 
constant Ki, indicating that unphosphorylated RCAN1 ap- 
peared to bind more strongly to calcineurin than p38 MAP 
kinase-phosphorylated RCAN1. The substrate specificity 
constant kcat/Km of RCAN1 was calculated as (0.590.15)   
Table 1  Kinetic parameters of calcineurin toward different substrates 
Substrate Km (µmol L
1) kcat (s1) 
RCAN1 WT 2.697±0.516 0.158±0.009 
RCAN1 S108AS112A 4.456±0.313 0.148±0.004 
NFATa) 2.04 0.11 
a) NFAT data are from a published paper [28]. 
105 M1 s1, which was similar to that of the calcineurin- 
catalyzed NFAT dephosphorylation [28], suggesting that 
p38 MAP kinase-phosphorylated RCAN1 may be a physi-
ological substrate for calcineurin in vivo. 
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Figure 4  Identification of p38α MAP kinase phosphorylation sites in RCAN1 S108A/S112A by mass spectrometry. A, The MS/MS spectrum of a triply 
charged ion at m/z 796.39 for MH3
3+ corresponding to the mass of the mono-phosphorylated peptide LYFAQTLHIGSSHLAPPNPDK. A loss of 98 Da 
(H3PO4) was observed for the precursor ion under the higher energy collision dissociation (HCD). The labeled peaks correspond to the masses of the y and b 
ions of the modified peptides. The y10 ion was observed to have a high intensity compared with the phosphorylated y10 ion, as shown in the inserted figure, 
suggesting that Ser-11 is the major phosphorylated residue. B, The MS/MS spectrum of a triply charged ion at m/z 745.03 for MH3
3+ corresponding to the 
mass of the mono-phosphorylated peptide QVEDATPVINYDLLYAISK. The labeled peaks correspond to the masses of the b and y ions of the 
mono-phosphorylated peptide, indicating that phosphorylation is on the Thr-6 residue. C, The MS/MS spectrum of a quadruply charged ion at m/z 993.18 for 
MH3
3+ corresponding to the mass of the mono-phosphorylated peptide YELHAATDPTPSVVVHVCESD- QENEEEEEEMER in which the Cys residue was 
carbamidomethylated. The loss of 98 Da (H3PO4) was observed for precursor ions under HCD. The labeled peaks correspond to the masses of the b and y  
ions of the mono-phosphorylated peptide, indicating that phosphorylation is on the Thr-10 residue. 
3  Discussion 
RCANs were first identified using screens for calcineurin 
binding proteins in fungi [25]. The overexpression of the 
yeast protein RCN1 or human RCAN1 inhibited at least two 
independent functions of calcineurin in yeast, the activation 
of the transcription factor Tcn1p and the inhibition of the 
H+/Ca2+ exchanger Vcx1p. Signaling via calmodulin, cal-
cineurin, and Tcn1p induced RCN1 expression, suggesting 
that RCN1 operates as an endogenous feedback inhibitor of 
calcineurin [24]. Human RCAN1 proteins are expressed in 
diverse cell types, including neurons and muscles [2931], 
and have complex effects in cells. However, the precise 
mechanisms and detailed roles of RCANs in calcineurin 
signaling are still unclear.  
RCAN1 has been reported to be phosphorylated by vari-
ous kinases, such as glycogen synthase kinase 3 (GSK-3) 
[27,32], ERK2 MAP kinase [27], big MAP kinase 1 (BMK1) 
[33], NFB-inducing kinase (NIK) [34], TGF-β-activated 
kinase 1 (TAK1) [35], dual specificity tyrosine phosphory- 
lation-regulated kinase 1A (Dyrk1A) [36] and protein ki-
nase A (PKA) [37]. The phosphorylation of RCAN1 has 
been shown to regulate calcineurin activity both positively 
and negatively. The central region of RCAN1 contains a 
perfect match to the GSK-3 consensus phosphorylation site 
(S108) [27] in the SP repeat of RCAN1. Phosphorylation by  
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Figure 5  Dephosphorylation of RCAN1 WT and S108A/S112A by cal-
cineurin. A, The time courses of p-RCAN1 WT (curve 2) and S108A/ 
S112A (curve 1) dephosphorylation by calcineurin. B, The dependence of 
the initial rate of the calcineurin-catalyzed reaction on the concentration of 
p-RCAN1 WT (open circle) and p-RCAN1 S108A/S112A (solid circle). 1  
µmol L1 calcineurin was used as the phosphatase. 
GSK-3 requires a priming phosphorylation at a nearby site 
(S112) by ERK2 [27]. The GSK-3-mediated phosphoryla-
tion of RCAN1 activates calcineurin signaling in vivo [32]. 
Similarly, TAK1 phosphorylates RCAN1 at two positions, 
S94 and S136, converting it from an inhibitor to a facilitator 
of calcineurin–NFAT signaling [35]. BMK1 can phosphor-
ylate RCAN1 at S112, and the BMK1-mediated phosphor- 
ylation of RCAN1 promotes the dissociation of RCAN1 
from calcineurin, thereby relieving its inhibition of cal-
cineurin activity [33]. In contrast, a recent report showed 
that Dyrk1A can phosphorylate RCAN1 at S112 and T192, 
and the phosphorylation of RCAN1 at T192 by Dyrk1A 
increases its ability to inhibit calcineurin phosphatase activ-
ity [36]. The PKA-mediated phosphorylation of RCAN1 at 
an unknown phosphorylation site has also been shown to 
enhance its inhibition of calcineurin-mediated gene tran-
scription [37]. In addition to regulating calcineurin activity, 
the phosphorylation of RCAN1 affects its protein stability 
through the ubiquitin-proteasome pathway [38]. The phos-
phorylation of RCAN1 at the FLISPP motif controls the 
half-life of RCAN1 by accelerating its degradation, while 
phosphorylation of the C-terminal region by NIK blocks 
degradation and increases the stability of the protein.  
In the present study, we examined the putative role of 
p38 MAP kinase in the regulation of RCAN1 activity. We 
found that p38 MAP kinase phosphorylates RCAN1 on 
multiple sites both within and outside the FLISPP motif in 
vitro (S93, S108, S112, T124 and T153). Thus, p38 MAP 
kinase-mediated RCAN1 phosphorylation may represent a 
previously unrecognized MAP kinase cascade that regulates 
calcineurin signaling. The physiological significance of the 
MAP kinase regulation of calcineurin activation through the 
phosphorylation of RCAN1 will be an interesting topic for 
future studies. 
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